Literature DB >> 35308910

Extraction of Electronic Health Record Data using Fast Healthcare Interoperability Resources for Automated Breast Cancer Risk Assessment.

Julia E McGuinness1,2,3, Tianmai M Zhang1, Kevin Cooper4, Arusha Kelkar1, Jill Dimond3, Virginia Lorenzi1, Katherine D Crew2,3,5, Rita Kukafka1.   

Abstract

Women at high risk for breast cancer may benefit from enhanced screening and risk-reduction strategies. However, limited time during clinical encounters is one barrier to routine breast cancer risk assessment. We evaluated if electronic health record (EHR) data downloaded using Fast Healthcare Interoperability Resources (FHIR) is sufficient for breast cancer risk calculation in our decision support tools, RealRisks and BNAV. We accessed EHR data using FHIR for six patient advocates, and downloaded and parsed XML documents. We searched for relevant clinical variables, and evaluated if data was sufficient to calculate risk using validated models (Gail, Breast Cancer Screening Consortium [BCSC], BRCAPRO). While only one advocate had sufficient EHR data to calculate risk using the BCSC model only, we identified variables including age, race/ethnicity, mammographic density, and prior breast biopsy in most advocates. EHR data from FHIR could be incorporated into automated breast cancer risk calculation in clinical decision support tools. ©2021 AMIA - All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 35308910      PMCID: PMC8861753     

Source DB:  PubMed          Journal:  AMIA Annu Symp Proc        ISSN: 1559-4076


  33 in total

1.  Usability Testing of a Web-Based Decision Aid for Breast Cancer Risk Assessment Among Multi-Ethnic Women.

Authors:  Austin M Coe; William Ueng; Jennifer M Vargas; Raven David; Alejandro Vanegas; Katherine Infante; Meghna Trivedi; Haeseung Yi; Jill Dimond; Katherine D Crew; Rita Kukafka
Journal:  AMIA Annu Symp Proc       Date:  2017-02-10

2.  Evaluating the Coverage of the HL7 ® FHIR ® Standard to Support eSource Data Exchange Implementations for use in Multi-Site Clinical Research Studies.

Authors:  Maryam Y Garza; Michael Rutherford; Sahiti Myneni; Susan Fenton; Anita Walden; Umit Topaloglu; Eric Eisenstein; Karan R Kumar; Kanecia O Zimmerman; Mitra Rocca; Gideon Scott Gordon; Sam Hume; Zhan Wang; Meredith Zozus
Journal:  AMIA Annu Symp Proc       Date:  2021-01-25

3.  Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.

Authors:  D Craig Allred; Stewart J Anderson; Soonmyung Paik; D Lawrence Wickerham; Iris D Nagtegaal; Sandra M Swain; Elefetherios P Mamounas; Thomas B Julian; Charles E Geyer; Joseph P Costantino; Stephanie R Land; Norman Wolmark
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

4.  Validation studies for models projecting the risk of invasive and total breast cancer incidence.

Authors:  J P Costantino; M H Gail; D Pee; S Anderson; C K Redmond; J Benichou; H S Wieand
Journal:  J Natl Cancer Inst       Date:  1999-09-15       Impact factor: 13.506

5.  Automatic Genetic Risk Assessment Calculation Using Breast Cancer Family History Data from the EHR compared to Self-Report.

Authors:  Margaret Sin; Julia E McGuinness; Meghna S Trivedi; Alejandro Vanegas; Thomas B Silverman; Katherine D Crew; Rita Kukafka
Journal:  AMIA Annu Symp Proc       Date:  2018-12-05

Review 6.  The use of tamoxifen and raloxifene for the prevention of breast cancer.

Authors:  D Lawrence Wickerham; Joseph P Costantino; Victor G Vogel; Walter M Cronin; Reena S Cecchini; Leslie G Ford; Norman Wolmark
Journal:  Recent Results Cancer Res       Date:  2009

7.  Electronic health records contain dispersed risk factor information that could be used to prevent breast and ovarian cancer.

Authors:  Thomas H Payne; Lue Ping Zhao; Calvin Le; Peter Wilcox; Troy Yi; Jesse Hinshaw; Duncan Hussey; Alex Kostrinsky-Thomas; Malika Hale; John Brimm; Fuki M Hisama
Journal:  J Am Med Inform Assoc       Date:  2020-07-01       Impact factor: 4.497

8.  Prototypical Clinical Trial Registry Based on Fast Healthcare Interoperability Resources (FHIR): Design and Implementation Study.

Authors:  Christian Gulden; Romina Blasini; Azadeh Nassirian; Alexandra Stein; Fatma Betül Altun; Melanie Kirchner; Hans-Ulrich Prokosch; Martin Boeker
Journal:  JMIR Med Inform       Date:  2021-01-12

9.  Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.

Authors:  Jack Cuzick; Ivana Sestak; Simon Cawthorn; Hisham Hamed; Kaija Holli; Anthony Howell; John F Forbes
Journal:  Lancet Oncol       Date:  2014-12-11       Impact factor: 41.316

10.  Study protocol: Randomized controlled trial of web-based decision support tools for high-risk women and healthcare providers to increase breast cancer chemoprevention.

Authors:  Katherine D Crew; Thomas B Silverman; Alejandro Vanegas; Meghna S Trivedi; Jill Dimond; Jennie Mata; Margaret Sin; Tarsha Jones; Mary Beth Terry; Wei-Yann Tsai; Rita Kukafka
Journal:  Contemp Clin Trials Commun       Date:  2019-08-22
View more
  1 in total

1.  Strategies to Identify and Recruit Women at High Risk for Breast Cancer to a Randomized Controlled Trial of Web-based Decision Support Tools.

Authors:  Julia E McGuinness; Gauri Bhatkhande; Jacquelyn Amenta; Thomas Silverman; Jennie Mata; Ashlee Guzman; Ting He; Jill Dimond; Tarsha Jones; Rita Kukafka; Katherine D Crew
Journal:  Cancer Prev Res (Phila)       Date:  2022-06-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.